Active CNS 🧠 disease is a major challenge for #lymphoma pts planned for CAR T cells. CNS bridging #radiotherapy can rapidly cytoreduce these high risk pts. The Memorial Sloan Kettering Cancer Center initial experience out in Blood Advances Memorial Sloan Kettering Radiation Oncology ashpublications.org/bloodadvances/…

Were you treated for #HodgkinLymphoma between the ages of 15-39 and experienced financial hardships due to costs associated with your treatment and long-term impacts on your life? If so, we want to hear from you: bit.ly/3SLZ0ke

Another successful COG Fall Group Meeting in the books! Aside from discussing current and future Children’s Oncology Group trials, the best part is hanging out with my favorite peds radiation oncologists, Suzanne Wolden, Dana L. Casey Kathryn Ries Tringale Chris Jackson, MD, MS #COGFALL2024 #NOLA #MSKCC

Join us at #ASTRO24 for our UC San Diego #RadOnc Residency Meet & Greet! Monday, Sept. 30th from 4-6 at Root & Vine (999 9th St NW). Register here: forms.gle/PYZ147JmuReBNW…

Gustav Cederquist presenting impressive results of RT for secondary CNS lymphoma Brandon Imber Memorial Sloan Kettering Radiation Oncology

Kathryn Ries Tringale presenting on cerebral atrophy after WHRT for primary CNS lymphoma - reduced-dose WBRT does not cause more cerebral atrophy compared to other consolidation strategies. Brandon Imber Memorial Sloan Kettering Radiation Oncology

Dr Zach Moore presents results of a study on MALT involving the dura Brandon Imber Memorial Sloan Kettering Radiation Oncology

Featured today by MSK Library: Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020 #MedicalStudy #CNSLymphoma #Relapse #LongitudinalAnalysis #Patients #CancerDiagnosis #OncologyResearch

In a large cohort of PCNSL patients with long follow-up, Kathryn Ries Tringale, Michael Scordo, @Brandon_Imber found cerebral atrophy rates were similar across consolidation strategies suggesting similar neurotoxicity. Read it in the #RedJournal: tinyurl.com/redtring

A new study by Chris Jackson, MD, MS & Dan Higginson identified the optimal dose of a type of targeted radiation used to treat people with cancer that has spread to their spine. These new recommendations minimize the risk of developing a complication during therapy known as

Our work identifying a new spinal cord constraint for spine SBRT was published yesterday in JAMA Oncology Dan Higginson. Here, a thread: jamanetwork.com/journals/jamao…

SRO shares "The contemporary spectrum of radiotherapy for hematologic malignancies involving the central nervous system: From focal therapy to craniospinal" by Drs. Cederquist, Tringale Kathryn Ries Tringale, Yahalom JOACHIM YAHALOM, & Imber Brandon Imber sciencedirect.com/science/articl…

The National Comprehensive Cancer Network (NCCN) Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient. This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: bit.ly/4iQpoo1.

Moores member Kathryn Ries Tringale will be sharing the latest insights into deep learning-based MRI therapeutics at #ASCO25 🔬 Join us at 11:15 a.m. for her presentation during a rapid oral abstract session focusing on developmental therapeutics! 🔗 Learn more about the session:

Phase I Study of split course bridging RT prior to CAR-T cell therapy for R/R B- cell lymphoma: citoreduction and immune priming. Impressive results! Brandon Imber #ICML18

We stan bridging RT before CAR! #18ICML - 116 pts with comprehensive RT to all PET avid sites - higher RT dose = less post-CAR G3+ CRS - higher LDH after RT = more G3+ CRS/ICANS Who else is using multisite bridging RT before CAR? #lymsm #tcellrx

Amazing work Bea Fregonese presenting our initial results on financial toxicity and decision regret in #aya #hodgkinlymphoma survivors. There’s still time for patients to fill out the survey: bit.ly/3SLZ0ke

Double trouble! Congrats to Rosh on his important work showing that bridging RT prior to CAR T cells is safe and probably needs greater personalization by tumor genetics. Great work! Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center #18ICML

Beyond proud of our Memorial Sloan Kettering Radiation Oncology hematology research team! Exciting research at the forefront of all aspects of #18ICML!! Hopefully the Lago view makes up for all the hard work 😉 Memorial Sloan Kettering Cancer Center

Proton CSI vs VMAT CSI for LMD Protons more systemic therapy after CSI 92% vs 46% Protons less Anemia 20% vs 61%, leukopenia 10% vs 46%, lymphopenia 67% vs 88% OS proton CSI 11 mo vs 5 mo (no diff ECOG adjusted) sciencedirect.com/science/articl…